0 CONTACTS Postal Address: Kintampo Health Research Centre Post Office Box 200, Kintampo - Brong Ahafo Ghana - West Africa. Our Website Address: www.kintampo-hrc.org For enquiries contact us through: [email protected] For enquiries on Ethics approvals contact us through: [email protected] Connect with us through the following social media platforms: https://facebook.com/kintampohrc https://twitter.com/kintampohrc http://www.linkedin.com/company/kintampo-health-research-centre I Table of Contents CONTACTS ..................................................................................................................................................... I ACRONYMS/ ABBREVIATIONS ...................................................................................................................... V ACKNOWLEDGMENT .................................................................................................................................. VII MISSION AND VISION STATEMENTS ........................................................................................................... IX FORWARD .................................................................................................................................................... X EXECUTIVE SUMMARY FROM DIRECTOR .................................................................................................... XI CHAPTER 1: ORGANIZATIONAL OVERVIEW ................................................................................................. 1 Organogram ................................................................................................................................................ 1 Administration ............................................................................................................................................. 2 Accounts Departments ................................................................................................................................ 6 Computer center (CC) .................................................................................................................................. 9 Clinical trial facility ..................................................................................................................................... 11 Clinical Laboratory ..................................................................................................................................... 12 Bacteriology ........................................................................................................................................... 12 Clinical Chemistry ................................................................................................................................. 13 Entomology ............................................................................................................................................ 13 Haematology .......................................................................................................................................... 13 Immunology ........................................................................................................................................... 13 Molecular Biology ................................................................................................................................. 14 Micronutrient ......................................................................................................................................... 14 Parasitology............................................................................................................................................ 14 Quality Assurance Systems .................................................................................................................... 14 Scientific Review Committee ..................................................................................................................... 16 Institutional Ethics Committee (IEC) .......................................................................................................... 17 Biostatistics Unit ........................................................................................................................................ 19 CHAPTER 2: RESEARCH PROGRAMMES ..................................................................................................... 20 Kintampo Health and Demographic Surveillance System (KHDSS)........................................................ 20 CHAPTER 3: RESEARCH PROJECTS .............................................................................................................. 22 Antibiotics studies .................................................................................................................................. 22 Community-level antibiotic access and use in low- and middle-income countries; Finding targets for social interventions to improve rational antimicrobial use. .................................................................. 22 Bioequivalence study ............................................................................................................................. 25 A balanced, randomized, two treatment, two-period, two-sequence single dose crossover, open- label,analyst blind and single centre bioequivalence study of test product; Tenofovek of Danadams Pharmaceuticals Industry Ltd., Ghana and reference product; Viread (Gilead Sciences, Inc., CA, USA) inhealthy, Ghanaian adult, male, human participants under fasting conditions. ................................. 25 II Clinical Trials: ............................................................................................................................................. 27 A prospective study to estimate the incidence of diseases specified as adverse events of special interest, of other adverse events leading to hospitalization or death, and of meningitis in infants and young children in Sub-Saharan Africa prior to implementation of the RTS,S/AS01E candidate vaccine. ............................................................................................................................................................... 27 Phase IIIb randomized, open, controlled, multi-center study to evaluate the immunogenicity and safety of the RTS,S/AS01E candidate malaria vaccine, when administered as primary vaccination at 6, 7.5 and 9 months of age with or without co-administration of measles, rubella and yellow fever vaccines followed by an RTS,S/AS01E booster vaccination 18 months post Dose 3, to children living in sub-Saharan Africa. ................................................................................................................................ 29 Study of immune correlates of protection against malaria after vaccination with RTS,S/AS01E: a comprehensive immunological arm of a Phase III double-blind, randomized, controlled multi-center trial (MAL067) ........................................................................................................................................ 31 Environmental studies ............................................................................................................................... 33 Understanding adoption of clean cookstoves ....................................................................................... 33 Case study of Ghana’s Liquefied Petroleum Gas Scale Up, adoption and sustainability ....................... 35 Adult Lung Function Study ..................................................................................................................... 37 Innovative technology research: ................................................................................................................ 39 Continuum of Care (CoC) card for family planning implementation research project .......................... 39 Validation of a Protein Creatinine (PrCr) dipstick diagnostic test for proteinuria screening in antenatal care clinics in Ghana .............................................................................................................................. 41 Sexual and Reproductive Health (SRH) ...................................................................................................... 43 Knowledge, Community Perceptions, and Treatment Options for Infertile Males and Females in Central Ghana. ....................................................................................................................................... 43 Mental Health ............................................................................................................................................ 45 Prevalence and correlates of antenatal depression among pregnant young women in Accra metropolitan area, Ghana ...................................................................................................................... 45 Validation of the Symptom Checklist-90-R (SCL-90-R) among adolescents in the Kintampo districts in Ghana. .................................................................................................................................................... 47 CHAPTER 5: Malaria studies ....................................................................................................................... 49 Strengthening Quality of Malaria Care and Surveillance in Ghanaian Communities ............................ 49 Epidemiology of malaria transmission intensity in sub-saharan African